Pharmaceutical Business review

Gilead takes over YM BioSciences

A Gilead subsidiary acquired all YM’s outstanding common shares as per the terms of a plan of arrangement.

Thus, YM has become a wholly-owned subsidiary of Gilead.

YM shareholders will be entitled to receive $2.95 per common share in cash, and holders of warrants and stock options will be eligible for a cash payment equal to the difference between $2.95 and the exercise price of such warrant or stock option.